Obstructive Sleep ApneaNORRISNCT05245240
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome
A study testing Dietary and physical intervention in people with Obstructive Sleep Apnea and Obesity, run by Faculty Hospital Kralovske Vinohrady at 1 site in Czechia.
Trial summary
Obstructive sleep apnea syndrome (OSA) represents highly prevalent (typically overlooked, undiagnosed and untreated) disorder significantly increasing cardiovascular, cancer and overall mortality as well as increasing the risk of Type 2 diabetes and liver steatohepatitis. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obstructive Sleep Apnea, Obesity
- What is being tested?
- Dietary and physical intervention
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteCzechia
- Study dates
- 1 Jan 2022to Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- mild (AHI < 10) or severe (AHI > 30) OSA diagnosed by home sleep study
- BMI 30-40 kg/m2
- age 18 - 65 years
- absence of diabetes mellitus (fasting glucose level < 7 mmol/l, HBA1c < 48 mmol/l and oGTT < 11.1 mmol/L 2 hours after 75g oral glucose load)
- no treatment with drugs affecting lipolysis (betablockers, alpha adrenergic blockers, glucocorticoids).
Who cannot join
- cardiac, renal or respiratory; chronic inflammatory or cancer disease
- body weight change more than 5 kg in last 3 months
- inability to participate in the life-style program
- inability to give an informed consent
- participation in another research project
- pregnancy or planned pregnancy during the study period
Trial locations and contacts
1 site in 1 country.
Czechia1 site, 1 recruiting
- Recruiting
University Hospital Královské Vinohrady
Prague, 100 34
Jan Polak, MD, PhD, +420267162710, jan.polak@lf3.cuni.cz
About this study
Obstructive sleep apnea syndrome (OSA) represents highly prevalent (typically overlooked, undiagnosed and untreated) disorder significantly increasing cardiovascular, cancer and overall mortality as well as increasing the risk of Type 2 diabetes and liver steatohepatitis. Unfortunately, adherence to state-of-the-art therapy with continuous positive airway pressure devices (CPAP) is poorly tolerated by patients, rendering a significant proportion (~60-70 %) of them at undiminished cardiovascular and metabolic risk warranting development of innovative, pharmacological, treatment options.
The overarching theme of this project is that metabolic impairments associated with OSA (e.g. Type 2 diabetes mellitus and non-alcoholic steatohepatitis) are causally mediated by elevated levels of circulating free fatty acids (FFA) originating from hypoxia-induced adipose tissue lipolysis. Increased plasma FFA subsequently induce insulin resistance, β-cell dysfunction, increase hepatic glucose output and stimulate lipid storage in liver. The investigators recently proved that hypoxia represents a powerful stimulus for adipocyte lipolysis and that experimental pharmacological inhibition of lipolysis prevented development of Type 2 diabetes in a mouse model of OSA. The goal of the project is to understand adipose tissue lipolysis derangements in OSA subjects and to evaluate the feasibility of lifestyle intervention as a mean to reduce spontaneous lipolysis.
Read the detailed description
Obstructive sleep apnea (OSA) is a common condition affecting 5-15% of the general population characterized by a repetitive collapse of the upper airway during sleep. The ensuing apneas and hypopneas lead to episodic drops in oxyhemoglobin saturation (intermittent hypoxia) and recurrent arousals from sleep. Research over the last decade has demonstrated that OSA is independently associated with insulin resistance, glucose intolerance, type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH), however, molecular mechanisms mediating this causal link remain unknown. Increased sympathetic autonomic activity, alterations in corticotropic function, augmented oxidative stress and activation of inflammatory pathways represent possible intermediate mechanisms.
Research interest of the investigators is to explore the role of enhanced adipose tissue lipolysis and circulating free fatty acid (FFA) levels as a causal factor impairing metabolic homeostasis in OSA. The investigators as well as other researchers demonstrated that exposure to sustained and intermittent hypoxia increased adipocyte lipolysis in-vitro and in mice.
Enhanced spontaneous lipolysis in subcutaneous adipose tissue with subsequent FFA release into circulation is a predominant source of plasma FFA in obese and insulin resistant subjects. Plasma FFA levels subsequently provide energy for working muscle, however, it has been also recognized that FFA mediate important regulatory and endocrine functions. Indeed, obese individuals as well as T2DM patients are often characterized by higher FFA in plasma and elevated FFA levels are considered to be a causal factor inducing insulin resistance in muscle and liver and hampering insulin secretion and β-cells ultimately contributing to the development of Type 2. diabetes mellitus (T2DM). Significant advances were made in understanding molecular mechanisms linking FFA with insulin resistance: ranging from mechanistic substrate competition between FFA oxidation and glucose utilization with allosteric inhibition of glycolytic pathway enzymes to accumulation of several lipid-based intermediates with profound intracellular regulatory functions, such as LCFA-CoA (long-chain fatty acid-coenzyme A) and activation of specific isoforms of protein-kinase C (isoforms β, δ and θ) which subsequently phosphorylates several intracellular proteins including a key element in insulin receptor-mediated signal transduction, IRS-1 (insulin receptor substrate).
Lifestyle interventions (regular physical activity and dietary intervention) play a central role in the management of obesity, livers steatosis and Type 2 diabetes by multiple mechanisms, including reduction in spontaneous adipose tissue lipolysis. Human studies demonstrated decreased lower spontaneous lipolysis in active compared to sedentary subjects and decreased lipolytic rate was reported after 3-month exercise training and diet-induced weight loss. Molecular mechanisms mediating decreased lipolysis include improved sensitivity of adipocytes to insulin, a major anti-lipolytic hormone, as well as increased sensitivity to anti-lipolytic α2-adrenergic effect of circulating catecholamines. Importantly, using adipose tissue microdialysis technique, the investigators observed reduced α2-adrenergic signaling in diabetic subjects with severe OSA, opening a rationale for exercise-based interventions to reduce lipolysis in OSA. However, future research focusing on mechanisms behind dysregulated adipose tissue lipolysis in OSA is needed, as hypoxia (characteristic for OSA) directly induces multiple transcriptional and mitochondrial changes in adipocytes stimulating lipolysis in vitro and no studies evaluated whether adipose tissue lipolysis (including α2/β2 adrenergic signaling balance) can in fact be modified by lifestyle interventions in subjects with OSA. Besides beneficial metabolic effects of lifestyle-induced weight loss, adiposity reduction in the whole body and subsequent reduction in tongue / parapharyngeal tissue volume helps to keep airways opened during sleep (reducing the severity of OSA) and helps to better tolerate CPAP treatment (less external positive pressure required to keep airways opened). Lifestyle intervention thus induces additional beneficial effects, independent of molecular changes in adipose tissue and liver.
- Conditions
- Obstructive Sleep Apnea, Obesity
- Being tested
- Dietary and physical intervention
- Medical subject headings
- Sleep Apnea, Obstructive, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary and physical interventionProcedure or surgery
Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.
Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Severe OSA group | Experimental | Dietary and physical activity intervention Receives: Procedure: Dietary and physical intervention |
| Mild OSA group | Experimental | Dietary and physical activity intervention Receives: Procedure: Dietary and physical intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glycerol release (lipolysis) in adipose tissue measured by microdialysis
Changes in interstitial glycerol concentration in adipose tissue before and after exercise and dietary intervention
Measured: Baseline and 6 months
Secondary outcomes (1)
Weight loss measurements
5-10% weight loss by exercise and dietary intervention
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2022
- Study start1 Jan 2022
- Primary completionDec 2024 (estimated)
- Study completionDec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obstructive Sleep ApneaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Faculty Hospital Kralovske Vinohrady
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Jan Polak, Faculty Hospital Kralovske Vinohrady
- Investigators
- Jan Polak, MD, PhD, Principal investigator, Vascular surgery, University hospital Královské Vinohrady, Prague
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05245240
- Sponsor's protocol ID
- NU21-01-00259
- Acronym
- NORRIS
- Status last verified
- Feb 2022
- First submitted
- 3 Feb 2022
- Last updated
- 17 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome
- ClinicalTrials.gov ID
- NCT05245240
- Acronym / sponsor ID
- NORRIS / NU21-01-00259
- Conditions
- Obstructive Sleep Apnea, Obesity
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Faculty Hospital Kralovske VinohradyOther government
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- Dec 2024 (estimated)
- Study completion
- Dec 2024 (estimated)
- First posted
- 17 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obstructive sleep apnea syndrome (OSA) represents highly prevalent (typically overlooked, undiagnosed and untreated) disorder significantly increasing cardiovascular, cancer and overall mortality as well as increasing the risk of Type 2 diabetes and liver steatohepatitis. Unfortunately, adherence to state-of-the-art therapy with continuous positive airway pressure devices (CPAP) is poorly tolerated by patients, rendering a significant proportion (~60-70 %) of them at undiminished cardiovascular and metabolic risk warranting development of innovative, pharmacological, treatment options.
The overarching theme of this project is that metabolic impairments associated with OSA (e.g. Type 2 diabetes mellitus and non-alcoholic steatohepatitis) are causally mediated by elevated levels of circulating free fatty acids (FFA) originating from hypoxia-induced adipose tissue lipolysis. Increased plasma FFA subsequently induce insulin resistance, β-cell dysfunction, increase hepatic glucose output and stimulate lipid storage in liver. The investigators recently proved that hypoxia represents a powerful stimulus for adipocyte lipolysis and that experimental pharmacological inhibition of lipolysis prevented development of Type 2 diabetes in a mouse model of OSA. The goal of the project is to understand adipose tissue lipolysis derangements in OSA subjects and to evaluate the feasibility of lifestyle intervention as a mean to reduce spontaneous lipolysis.
Detailed description
Obstructive sleep apnea (OSA) is a common condition affecting 5-15% of the general population characterized by a repetitive collapse of the upper airway during sleep. The ensuing apneas and hypopneas lead to episodic drops in oxyhemoglobin saturation (intermittent hypoxia) and recurrent arousals from sleep. Research over the last decade has demonstrated that OSA is independently associated with insulin resistance, glucose intolerance, type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH), however, molecular mechanisms mediating this causal link remain unknown. Increased sympathetic autonomic activity, alterations in corticotropic function, augmented oxidative stress and activation of inflammatory pathways represent possible intermediate mechanisms.
Research interest of the investigators is to explore the role of enhanced adipose tissue lipolysis and circulating free fatty acid (FFA) levels as a causal factor impairing metabolic homeostasis in OSA. The investigators as well as other researchers demonstrated that exposure to sustained and intermittent hypoxia increased adipocyte lipolysis in-vitro and in mice.
Enhanced spontaneous lipolysis in subcutaneous adipose tissue with subsequent FFA release into circulation is a predominant source of plasma FFA in obese and insulin resistant subjects. Plasma FFA levels subsequently provide energy for working muscle, however, it has been also recognized that FFA mediate important regulatory and endocrine functions. Indeed, obese individuals as well as T2DM patients are often characterized by higher FFA in plasma and elevated FFA levels are considered to be a causal factor inducing insulin resistance in muscle and liver and hampering insulin secretion and β-cells ultimately contributing to the development of Type 2. diabetes mellitus (T2DM). Significant advances were made in understanding molecular mechanisms linking FFA with insulin resistance: ranging from mechanistic substrate competition between FFA oxidation and glucose utilization with allosteric inhibition of glycolytic pathway enzymes to accumulation of several lipid-based intermediates with profound intracellular regulatory functions, such as LCFA-CoA (long-chain fatty acid-coenzyme A) and activation of specific isoforms of protein-kinase C (isoforms β, δ and θ) which subsequently phosphorylates several intracellular proteins including a key element in insulin receptor-mediated signal transduction, IRS-1 (insulin receptor substrate).
Lifestyle interventions (regular physical activity and dietary intervention) play a central role in the management of obesity, livers steatosis and Type 2 diabetes by multiple mechanisms, including reduction in spontaneous adipose tissue lipolysis. Human studies demonstrated decreased lower spontaneous lipolysis in active compared to sedentary subjects and decreased lipolytic rate was reported after 3-month exercise training and diet-induced weight loss. Molecular mechanisms mediating decreased lipolysis include improved sensitivity of adipocytes to insulin, a major anti-lipolytic hormone, as well as increased sensitivity to anti-lipolytic α2-adrenergic effect of circulating catecholamines. Importantly, using adipose tissue microdialysis technique, the investigators observed reduced α2-adrenergic signaling in diabetic subjects with severe OSA, opening a rationale for exercise-based interventions to reduce lipolysis in OSA. However, future research focusing on mechanisms behind dysregulated adipose tissue lipolysis in OSA is needed, as hypoxia (characteristic for OSA) directly induces multiple transcriptional and mitochondrial changes in adipocytes stimulating lipolysis in vitro and no studies evaluated whether adipose tissue lipolysis (including α2/β2 adrenergic signaling balance) can in fact be modified by lifestyle interventions in subjects with OSA. Besides beneficial metabolic effects of lifestyle-induced weight loss, adiposity reduction in the whole body and subsequent reduction in tongue / parapharyngeal tissue volume helps to keep airways opened during sleep (reducing the severity of OSA) and helps to better tolerate CPAP treatment (less external positive pressure required to keep airways opened). Lifestyle intervention thus induces additional beneficial effects, independent of molecular changes in adipose tissue and liver.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Severe OSA group | Experimental | Procedure: Dietary and physical interventionDietary and physical activity intervention |
| Mild OSA group | Experimental | Procedure: Dietary and physical interventionDietary and physical activity intervention |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- mild (AHI < 10) or severe (AHI > 30) OSA diagnosed by home sleep study
- BMI 30-40 kg/m2
- age 18 - 65 years
- absence of diabetes mellitus (fasting glucose level < 7 mmol/l, HBA1c < 48 mmol/l and oGTT < 11.1 mmol/L 2 hours after 75g oral glucose load)
- no treatment with drugs affecting lipolysis (betablockers, alpha adrenergic blockers, glucocorticoids).
Key exclusion criteria (6 listed)
- cardiac, renal or respiratory; chronic inflammatory or cancer disease
- body weight change more than 5 kg in last 3 months
- inability to participate in the life-style program
- inability to give an informed consent
- participation in another research project
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary and physical interventionLow-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences. Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes. | Procedure or surgery | Mild OSA group, Severe OSA group |
Primary outcome
Glycerol release (lipolysis) in adipose tissue measured by microdialysis
Time frame: Baseline and 6 months
Changes in interstitial glycerol concentration in adipose tissue before and after exercise and dietary intervention
1 secondary outcome
Weight loss measurements
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2022.
- Individual participant dataSharing planned: No
Related trials for Obstructive Sleep Apnea
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 1/2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jan Polak, MD, PhD principal investigator
Vascular surgery, University hospital Královské Vinohrady, Prague
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dietary and physical intervention in people with Obstructive Sleep Apnea and Obesity, run by Faculty Hospital Kralovske Vinohrady at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jan Polak, MD, PhD (+420267162710, jan.polak@lf3.cuni.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glycerol release (lipolysis) in adipose tissue measured by microdialysis (time frame: Baseline and 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2022.